United States Patent & Trademark Office Grants Evoke Pharma a Formulation Patent Covering GIMOTI
Evoke Pharma, Inc. recently announced the United States Patent and Trademark Office (USPTO) issued US patent No. 11,628,150 under the title Nasal Formulations of Metoclopramide.
This patent expires in 2029 and covers the nasal solution of metoclopramide and its characteristics when formulated. The patent augments Evoke’s existing patent portfolio, which includes US FDA Orange Book-listed patents and other patents in the EU, Japan, Canada, and Mexico. The company will seek to list this patent in the FDA Orange-Book in the near term.
“We view this patent approval and the others we’ve received to date from the USPTO as evidence of the innovation behind our product, GIMOTI and its significant contribution to the GI community, particularly patients,” commented Matt D’Onofrio, President & COO. “This patent will continue to protect GIMOTI’s proprietary route of administration which is incredibly important to our commercial efforts.”
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized, and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the US to treat gastroparesis. For more information, visit www.EvokePharma.com.
Total Page Views: 928
